Compare IINN & VRCA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IINN | VRCA |
|---|---|---|
| Founded | 2018 | 2013 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 35.3M | 32.7M |
| IPO Year | 2021 | 2018 |
| Metric | IINN | VRCA |
|---|---|---|
| Price | $1.05 | $7.49 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 1 | 2 |
| Target Price | ★ $2.00 | N/A |
| AVG Volume (30 Days) | 128.4K | ★ 402.7K |
| Earning Date | 10-01-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $289,000.00 | ★ $30,829,000.00 |
| Revenue This Year | N/A | $373.65 |
| Revenue Next Year | $2,582.74 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 234.73 |
| 52 Week Low | $0.40 | $3.28 |
| 52 Week High | $1.65 | $9.82 |
| Indicator | IINN | VRCA |
|---|---|---|
| Relative Strength Index (RSI) | 47.98 | 58.37 |
| Support Level | $1.03 | $7.82 |
| Resistance Level | $1.18 | $9.78 |
| Average True Range (ATR) | 0.07 | 1.21 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 43.43 | 54.31 |
Inspira Technologies Oxy BHN Ltd is a specialty medical device company engaged in the research, development, manufacture, and marketing of proprietary respiratory support technology that is intended to provide an alternative to invasive mechanical ventilation (MV), which is the standard of care today for the treatment of respiratory failure. The respiratory care devices market is segmented geographically into North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa.
Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a contagious and pediatric viral skin disease, and common warts.